# Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

> **NCT00130702** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Myelogenous Leukemia, Acute

## Interventions

- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00130702
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130702, "Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00130702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*